Electroacupuncture at BL15 attenuates chronic fatigue syndrome by downregulating iNOS/NO signaling in C57BL/6 mice

Abstract:

Chronic fatigue syndrome (CFS) has a high incidence due to the increased pressure of daily life and work in modern society. Our previous clinical studies have found the effects of electroacupuncture (EA) on CFS patients, however, the mechanism of EA on CFS is still unknown. In this study, we investigated the effects of EA on cardiac function in a CFS mouse model to explore its underlying mechanism.

The mice were randomly divided into three groups: control, CFS, and CFS mice receiving EA (CFS + EA). After behavioral assessments and echocardiographic measurement, blood and heart tissue of the mice were collected for biochemical tests, and then we evaluated the effects of EA on the CFS mouse model when nitric oxide (NO) levels were enhanced by l-arginine.

The results showed that EA ameliorated the injured motor and cardiac function. Meanwhile, EA also inhibited increased expression of inducible nitric oxide synthase (iNOS) at heart tissue and the serum NO levels in mice subjected to sustained forced swimming stress. Furthermore, the NO level in serum increased with l-arginine administration, which blocked the effects of EA on CFS mice. This study suggested that EA could improve the motor function and cardiac function in CFS mice and its effects may be associated with the down-regulation of iNOS/NO signaling.

Source: Zhu Y, Wang J, Yao L, Huang Y, Yang H, Yu X, Chen X, Chen Y. Electroacupuncture at BL15 attenuates chronic fatigue syndrome by downregulating iNOS/NO signaling in C57BL/6 mice. Anat Rec (Hoboken). 2022 May 24. doi: 10.1002/ar.24953. Epub ahead of print. PMID: 35608198. https://pubmed.ncbi.nlm.nih.gov/35608198/

Known unknowns, and as yet medically unexplained diseases

Seen from the outside, the process of scientific exploration of diseases seems chaotic and confusing. Indeed, from within, it is tempting to deduce that clinical academics are chaotic and confused.

To be fair, that is an appropriate deduction. Einstein famously said, ‘If we knew what we were doing, it wouldn’t be called research.’ The vast majority of medical research can be compared to solving a particularly complex crossword puzzle. We start with the ‘easy answers’, then progress to the deducible, before staring endlessly at the problems that don’t make sense to us. The hope is that the pieces we already have will enable us to fill the gaps and produce a semblance of sense.

Practising medicine often does not allow this freedom of thought. If the CRP is falling, the antibiotics are working; if it is rising, they’re not; fracture is a fracture; air under the diaphragm represents burst viscera.

Where, then, do we place conditions that we don’t as yet have diagnostic tests for?

Read the rest of this article HERE.

Source: Known unknowns, and as yet medically unexplained diseases by David Strain. BMA, May 12, 2022. https://www.bma.org.uk/news-and-opinion/known-unknowns-and-as-yet-medically-unexplained-diseases

Chronic fatigue syndrome and occupational status: a retrospective longitudinal study

Dear Sir,

Occupational Medicine recently published a paper from Stevelink et al. [1] called ‘Chronic fatigue syndrome and occupational status: a retrospective longitudinal study’. Unfortunately, the paper features major technical and methodological errors that warrant urgent editorial attention.

To recap: The study started with 508 participants. The primary outcome was occupational status. Many participants had dropped out by follow-up—only 316, or 62%, provided follow-up data. Of those 316, 88% reported no change in employment status. As a group, the participants experienced either no changes or only insignificant ones in a range of secondary outcomes, including fatigue and physical function. The poor follow-up scores on fatigue and physical function alone indicate that the group remained, collectively, severely disabled after treatment.

In several sections of the paper, the authors’ description of their own statistical findings is incorrect. They make a recurring elementary error in their presentation of percentages. The authors repeatedly use the construction ‘X% of patients who did Y at baseline’ when they should have used the construction ‘X% of all 316 patients (i.e. those who provided follow-up data)’. This recurring error involving the core findings undermines the merit and integrity of the entire paper.

For example, in the Abstract, the authors state that ‘53% of patients who were working [at baseline] remained in employment [at follow-up]’. This is not accurate. Their own data (Table 2) show that 185 patients (i.e. 167 + 18) were working at baseline, and that 167 patients were working at both time points. In other words, the proportion working continuously was in fact 90% (i.e. 167 out of 185). The ‘53%’ that the authors refer to is the percentage of the sample who were employed at both time points (i.e. 167 out of 316), which is an entirely different subset. They have either misunderstood the percentage they were writing about, or they have misstated their own finding by linking it to the wrong percentage.

This error is carried over into the section on ‘Key Learning Lessons’, where the authors state that ‘Over half of the patients who were working at baseline were able to remain in work over the follow-up period…’ While 90% is certainly ‘over half’, it seems clear that this phrasing is again incorrectly referring to the 53% subset.

The same error is made with the other key findings. For example, the Abstract states that ‘Of the patients who were not working at baseline, 9% had returned to work at follow-up’. But as above, this is incorrect. A total of 131 patients (i.e. 104 + 27) were recorded as ‘not employed’ at baseline and 27 were recorded as not working at baseline but as working at follow-up. This is 21%, not 9%. Once again, the authors appear to misunderstand their own findings. The ‘9%’ they refer to is a percentage of the sample of 316; it is not, as they have it, a percentage of that subset of the sample who were initially unemployed. This erroneous ‘9%’ conclusion appears as well in the ‘Key Learning Lessons’ and in the Discussion.

And again, the authors state in the Abstract that ‘of those working at baseline, 6% were unable to continue to work at follow-up’, a claim they repeat in the section on ‘Key Learning Lessons’ and in the Discussion. This statement too is wrong. Once more, the authors mistakenly interpret a percentage of the sample of 316 as if it were a percentage of a targeted subset. In this case, they think they are referring to a percentage of patients working at baseline, but they are actually referring to a percentage of the full group that provided follow-up data.

The authors present the raw frequency data in Table 2. Readers can see for themselves how their sample of 316 patients is cross-tabulated into four subsets of interest (i.e. ‘working at baseline and follow-up’; ‘not working at baseline and follow-up’; ‘dropped out of work at follow-up’; ‘returned to work at follow-up’). From Table 2, it is clear that the prose provided in the body of the paper is at odds with the actual data.

It is undeniable that the text of this paper is replete with elementary technical errors, as described. Inevitably, the narrative is distorted by the authors’ failure to understand and correctly explain their own findings. It is unclear to us how these basic and self-evident errors were not picked up during peer review. Although we don’t know the identities of the peer reviewers, we speculate that groupthink and confirmation bias will have played their part. After all, it is generally reasonable for peer reviewers to presume that authors have understood their own computations.

There are several other features of this paper that cause concern. These include the following:

  • The authors state that they evaluated participants using guidance from the UK’s National Institute for Health and Care Excellence (NICE). (Presumably they are referring to the 2007 NICE guidance, not the revision published in October 2021.) But the reference for this statement is a 1991 paper that outlines the so-called ‘Oxford criteria’, a case definition that differs significantly from the 2007 NICE guidance. Moreover, in a paper about the same participant cohort previously published by Occupational Medicine—‘Factors associated with work status in chronic fatigue syndrome’—the authors state explicitly that these patients were diagnosed using the Oxford criteria. This inconsistency is non-trivial, because the differences between these two diagnostic approaches have substantive implications for how the findings should be interpreted. The authors’ confusion over the matter is hard to comprehend and raises fundamental questions about the validity of their research.

  • According to Table 1, there were either no changes or no meaningful changes in average scores for fatigue, physical function and multiple other secondary outcomes between the preliminary sample of 508 and the final follow-up sample of 316. The authors themselves acknowledge that the patients who dropped out before follow-up were likely to have had poorer health than those who remained. Therefore, the fact that Table 1 presents combined averages for the entire preliminary sample—i.e. combined averages for patients who dropped out and those who did not—muddies the waters. Presenting combined baseline scores for all patients will mask any declines that occurred for these variables in the subset who were followed up. It would have been far more appropriate to have isolated and presented the baseline data for the 316 followed up patients alone. Doing so would have reflected the authors’ research question more correctly, as well as enabling readers to make their own like-with-like comparisons.

  • Finally, the authors state that ‘Studies into CFS have placed little emphasis on occupational outcomes, including return to work after illness’. However, they conspicuously fail to mention the PACE trial, a high-profile large-scale British study of interventions for CFS. The PACE trial included employment status as one of four objective outcomes, with the data showing that the interventions used—the same ones as in the Occupational Medicine study—have no effect on occupational outcomes. This previous finding is so salient to the present paper that it is especially curious the authors have chosen to omit it. The omission is all the more disquieting given that the corresponding author of the paper was a lead investigator on the PACE trial itself.

Authors of research papers have an obligation to cite seminal findings from prior studies that have direct implications for the target research question. Not doing so—especially where there is overlapping authorship—falls far short of the common standards expected in scientific reporting.

Even putting these additional matters aside, the technical errors that undermine this paper’s reporting of percentages render its key conclusions meaningless. The sentences used to describe the findings are simply incorrect, and the entire thrust of the paper’s narrative is thereby contaminated. We believe that allowing the authors to publish a correction to these sentences would create only further confusion.

We therefore call on the journal to retract the paper.

Read the rest of this article HERE.

Source: Hughes BM, Tuller D. Chronic fatigue syndrome and occupational status: a retrospective longitudinal study. Occup Med (Lond). 2022 May 23;72(4):e1-e2. doi: 10.1093/occmed/kqac007. PMID: 35604311. https://academic.oup.com/occmed/article/72/4/e1/6590617?login=false (Full article)

An Unexpected Journey: The Lived Experiences of Patients with Long-Term Cognitive Sequelae After Recovering from COVID-19

Abstract:

This current study explored the lived experiences of patients with long-term cognitive sequelae after recovering from COVID-19. A qualitative design with in-depth interviews and an analysis inspired by Ricoeur’s interpretation theory was utilised. Contracting COVID-19 and suffering long-term sequelae presented as a life-altering event with significant consequences for one’s social, psychological and vocational being in the world in the months following the infection.

Patients living with long-term cognitive sequelae after COVID-19 were in an unknown life situation characterised by feelings of anxiety, uncertainty and concerns about the future, significantly disrupting their life trajectory and forcing them to change their ways of life. While awaiting studies on treatment, symptom management and recovery after persistent sequelae of COVID-19, clinicians and researchers may find inspiration in experiences of other health conditions with similar phenomenology, such as ME/chronic fatigue syndrome and chronic headaches.

Source: Loft MI, Foged EM, Koreska M. An Unexpected Journey: The Lived Experiences of Patients with Long-Term Cognitive Sequelae After Recovering from COVID-19. Qual Health Res. 2022 May 21:10497323221099467. doi: 10.1177/10497323221099467. Epub ahead of print. PMID: 35603563. https://pubmed.ncbi.nlm.nih.gov/35603563/

Impaired exercise capacity in post-COVID syndrome: the role of VWF-ADAMTS13 axis

Abstract:

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognised complication of acute SARS-CoV-2 infection, characterised by persistent fatigue, reduced exercise tolerance chest pain, shortness of breath and cognitive slowing. Acute COVID-19 is strongly linked with increased risk of thrombosis; a prothrombotic state, quantified by elevated Von Willebrand Factor (VWF) Antigen (Ag):ADAMTS13 ratio, and is associated with severity of acute COVID-19 infection. We investigated if patients with PCS also had evidence of a pro-thrombotic state associating with symptom severity.

In a large cohort of patients referred to a dedicated post-COVID-19 clinic, thrombotic risk including VWF(Ag):ADAMTS13 ratio, was investigated. An elevated VWF(Ag):ADAMTS13 ratio (≥1.5) was raised in nearly one-third of the cohort and four times more likely in patients with impaired exercise capacity as evidenced by desaturation ≥3% and/or rise in lactate level more than 1 from baseline on 1-minute sit to stand test and/or 6-minute walk test (p<0.0001). 20% (56/276) had impaired exercise capacity, of which 55% (31/56) had a raised VWF(Ag):ADAMTS13 ratio ≥1.5 (p<0.0001). FVIII and VWF(Ag) were elevated in 26% and 18% respectively and support a hypercoagulable state in some patients with PCS.

These findings suggest possible ongoing microvascular/endothelial dysfunction in the pathogenesis of PCS and highlight a potential role for antithrombotic therapy in the management of these patients.

Source: Prasannan N, Heightman M, Hillman T, Wall E, Bell R, Kessler A, Neave L, Doyle AJ, Devaraj A, Singh D, Dehbi HM, Scully M. Impaired exercise capacity in post-COVID syndrome: the role of VWF-ADAMTS13 axis. Blood Adv. 2022 May 11:bloodadvances.2021006944. doi: 10.1182/bloodadvances.2021006944. Epub ahead of print. PMID: 35543533; PMCID: PMC9098525. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098525/ (Full text)

Hyperbaric Oxygen for Treatment of Long COVID Syndrome (HOT-LoCO); Protocol for a Randomised, Placebo-Controlled, Double-Blind, Phase II Clinical Trial

Abstract:

Introduction: Long COVID, where symptoms persist 12 weeks after the initial SARS-CoV-2-infection, is a substantial problem for individuals and society in the surge of the pandemic. Common symptoms are fatigue, post-exertional malaise, and cognitive dysfunction. There is currently no effective treatment, and the underlying mechanisms are unknown although several hypotheses exist, with chronic inflammation as a common denominator. In prospective studies, hyperbaric oxygen therapy (HBOT) has been suggested to be effective for the treatment of similar syndromes such as chronic fatigue syndrome and fibromyalgia. A case series has suggested positive effects of HBOT in Long COVID. This randomised placebo-controlled clinical trial will explore HBOT as a potential treatment for Long COVID.

The primary objective is to evaluate if HBOT improves health related quality of life (HRQoL) for patients with Long COVID compared to placebo/sham. The main secondary objectives are to evaluate whether HBOT improves endothelial function, objective physical performance, and short term HRQoL.

Methods and Analysis: A randomised, placebo-controlled, double-blind, phase II clinical trial in 80 previously healthy subjects debilitated due to Long COVID, with low HRQoL. Clinical data, HRQoL-questionnaires, blood samples, objective tests and activity meter data will be collected at baseline. Subjects will be randomised to a maximum of 10 treatments with hyperbaric oxygen or sham treatment over six weeks. Assessments for safety and efficacy will be performed at six, 13, 26 and 52 weeks, with the primary endpoint (physical domains in RAND-36) and main secondary endpoints defined at 13 weeks after baseline. Data will be reviewed by an independent Data Safety Monitoring Board.

Ethics and Dissemination: The trial is approved by The Swedish National Institutional Review Board (2021-02634) and the Swedish Medical Product Agency (5.1-2020-36673). Positive, negative, and inconclusive results will be published in peer-reviewed scientific journals with open access.

Trial Registration NCT04842448. EudraCT: 2021-000764-30 Strengths and limitations of this trial Strengths -Randomised placebo-controlled, double-blind, parallel groups, clinical trial in compliance with ICH-GCP -Evaluation of safety and efficacy, including objective and explanatory endpoints -Independent Data Safety Monitoring Board (DSMB) Limitations -New syndrome with unknown mechanisms -Power calculation is based on similar syndromes -Selection bias as patients are enrolled from the same post-COVID clinic

Source: Anders KjellbergLina Abdel-HalimAdrian HasslerSara El GharbiSarah Al-EzerjawiEmil BoströmCarl Johan SundbergJohn PernowKoshiar MedsonJan KowalskiKenny A Rodriguez-WallbergXiaowei ZhengSergiu Bogdan CatrinaMichael RunoldMarcus StåhlbergJudith BruchfeldMalin Nygren-BonnierPeter Lindholm. Hyperbaric Oxygen for Treatment of Long COVID Syndrome (HOT-LoCO); Protocol for a Randomised, Placebo-Controlled, Double-Blind, Phase II Clinical Trial.

Neurological and Psychiatric Symptoms of COVID-19: A Narrative Review

Abstract:

Recently dubbed Long COVID or Long-Haul COVID, those recovering from the initial COVID-19 infection may maintain clinical signs for longer than two or more weeks following the initial onset of the infection. The virus can gain entry into the CNS through axonal transport mediated through the olfactory nerve or hematogenous spread and can also cross the blood–brain barrier to access the temporal lobe and the brainstem. The neurologic and neuropsychiatric symptoms associated with COVID-19 patients are becoming a highly studied area due to the increased frequency of reported cases.
Multiple hospital case series and observational studies have found a headache to be a common symptom among patients who are symptomatic with the SARS-CoV-2 virus. The headache described by many of these patients is similar to new daily persistent headache (NDPH). NDPH potentially develops in response to pro-inflammatory cytokines during a persistent systemic or CNS inflammation, mostly due to the initial infection. The treatments investigated were high-dose steroids, tetracycline derivatives, onabotulinum toxin type A, and long-term multidrug regimens. Among the identified symptoms of post-COVID-19 viral illness, fatigue appears to be the most ubiquitous. High-dose vitamin C is currently a suggested therapy proposed for its antioxidant, anti-inflammatory, and immunomodulatory properties.
The mental health consequences of this diagnosis are being identified among large portions of COVID-19 survivors. Among these consequences, cases of major depressive disorder (MDD) and anxiety are being reported and closely examined. The aim of this narrative review is to highlight the neurological and psychiatric symptoms that have been associated with Long-Haul COVID and their possible treatments.
Source: Edinoff AN, Chappidi M, Alpaugh ES, Turbeville BC, Falgoust EP, Cornett EM, Murnane KS, Kaye AM, Kaye AD. Neurological and Psychiatric Symptoms of COVID-19: A Narrative Review. Psychiatry International. 2022; 3(2):158-168. https://doi.org/10.3390/psychiatryint3020013 https://www.mdpi.com/2673-5318/3/2/13/htm (Full text)

Functional neurological disorder: new subtypes and shared mechanisms

Abstract:

Functional neurological disorder is common in neurological practice. A new approach to the positive diagnosis of this disorder focuses on recognisable patterns of genuinely experienced symptoms and signs that show variability within the same task and between different tasks over time.

Psychological stressors are common risk factors for functional neurological disorder, but are often absent.

Four entities—functional seizures, functional movement disorders, persistent perceptual postural dizziness, and functional cognitive disorder—show similarities in aetiology and pathophysiology and are variants of a disorder at the interface between neurology and psychiatry.

All four entities have distinctive features and can be diagnosed with the support of clinical neurophysiological studies and other biomarkers. The pathophysiology of functional neurological disorder includes overactivity of the limbic system, the development of an internal symptom model as part of a predictive coding framework, and dysfunction of brain networks that gives movement the sense of voluntariness.

Evidence supports tailored multidisciplinary treatment that can involve physical and psychological therapy approaches.

Source: Prof Mark Hallett, Selma Aybek, Prof Barbara A Dworetzky, Laura McWhirter, Prof Jeffrey P Staab, Prof Jon Stone.  Functional neurological disorder: new subtypes and shared mechanisms. The Lancet- Neurology 21 (6): 537-550 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00422-1/fulltext 

Functional neurological disorder and other unexplained syndromes

Abstract:

Functional neurological disorder is a syndrome of medically unexplained neurological symptoms. In The Lancet Neurology, Mark Hallett and colleagues review some of the potential explanations for functional neurological disorder and the evidence that supports these explanations.

The paper by Hallett and colleagues, however, is more than a Review: it is also a territorial claim, seeking to expand the boundaries of what should be considered functional neurological disorder. The details of this claim are unlikely to be controversial to any clinician working in the field: the presentations Hallett and colleagues describe are not new, even if they do not fall within the current classifications of the disorder. But the claim is nonetheless remarkable, as even a decade ago it would have been thought to be sheer folly. A good argument could then have been made that functional neurological disorder (or conversion disorder, as it was more formally known) was the most stigmatised of all disorders, even compared with other unexplained syndromes. What would have been the point of expanding the scope of a diagnosis that patients went to such lengths to avoid?

The expansive mood in the Review by Hallett and colleagues therefore reflects a striking transformation in the status of functional neurological disorder. Functional neurological disorder has become a diagnosis that a neurologist might be comfortable to give, and that a patient might be glad to receive.

Source: Kanaan, RA . Functional neurological disorder and other unexplained syndromes. The Lancet- Neurology 21 (6):499-500. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00095-3/fulltext

NICE sets out steps NHS must take to implement ME/CFS guidelines

Abstract:

The National Institute for Health and Care Excellence has issued an unprecedented implementation statement setting out the practical steps needed for its updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) to be implemented by the NHS.

Such statements are only issued when a guideline is expected to have a “substantial” impact on NHS resources, and this is thought to be the first. It outlines the additional infrastructure and training that will be needed in both secondary and primary care to ensure that the updated ME/CFS guideline, published in October 2021, can be implemented.

The statement is necessary because the 2021 guideline completely reversed the original 2007 guideline recommendations that people with mild or moderate ME/CFS be treated with cognitive behavioural therapy (CBT) and graded exercise therapy (GET). Instead, the 2021 guideline says that CBT should be only offered to support patients to manage their symptoms and that any exercise programme should be overseen by an ME/CFS specialist team.

Many areas have no or very limited specialist ME/CFS services, meaning that services must be commissioned, specialist health professionals need to be trained to deliver these services, and GPs need training in how to care for their patients. “With no nationally commissioned service for ME/CFS in either primary or secondary care, it will be for local systems to determine how to structure their services to achieve the aims of the guideline,” said Paul Chrisp, director of the Centre for Guidelines at NICE.

The 2007 recommendations were overturned during a long and difficult guideline development process. Patient groups had long argued that the recommendations were inappropriate, ineffective, and potentially harmful, and hindered research into the disease. But health professionals raised concerns about the proposed guidelines and the process that underpinned them. Just weeks before the final guideline was due to be published three members of the development committee resigned, royal colleges and other professional bodies signalled that they would not support it, and NICE had to delay publication. The guideline was finally published after a meeting was arranged with stakeholders to iron out differences, but concerns among medical leaders persisted.

When the 2021 guideline was published, Charles Shepherd, honorary medical adviser of the ME Association, told The BMJ that the recommendations were “something that currently cannot be coped with.” After publication of the implementation statement, he said, “I think NICE have gone as far as they can. It is now up to individual clinical services to reposition what they do in order to comply with the recommendations and for commissioners to start setting up new clinical services where none currently exist—especially in Wales and Northern Ireland.

“A lot of people with ME/CFS are clearly not getting the medical care and support that they need in both primary care and secondary care, especially those who are severely affected and do not have access to any form of domiciliary service or a dedicated inpatient facility.” He added: “It would obviously be helpful if the royal colleges could also express their support for implementation of the changes, as it’s not clear whether they remain unhappy with the recommendations downgrading CBT and the removal of GET.”

The same day NICE published its implementation statement, Sajid Javid, health and social care secretary, announced the publication of research priorities for ME/CFS by Action for ME, a charity that supports people with ME.  “We are committed to funding research into this important area,” he said. Javid and his chief scientific adviser, Lucy Chappell, will co-chair an advisory board of experts on ME/CFS, including patients, to discuss what needs to happen next and liaise with the devolved nations.

“We will be developing our own delivery plan later this year and will be working with stakeholders to understand how we can improve experiences and outcomes for people with these debilitating conditions,” he said. “At the heart of the delivery plan will be two core principles. Firstly, that we do not know enough about ME/CFS, which must change if we are to improve experiences and outcomes. Secondly, we must trust and listen to those with lived experience of ME/CFS.”

The BMJ asked three royal colleges for a response to the implementation statement, but none responded before publication.

Source: Ingrid Torjesen. NICE sets out steps NHS must take to implement ME/CFS guidelines. BMJ 2022;377:o1221. https://www.bmj.com/content/377/bmj.o1221